Status:
NOT_YET_RECRUITING
Prostate Irreversible Electroporation Study
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Prostate Cancer
Eligibility:
MALE
40-85 years
Phase:
NA
Brief Summary
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, inc...
Eligibility Criteria
Inclusion
- Men aged between 40 - 85 years
- Visible index lesion(s) on MRI
- Found to have localized prostate cancer after MRI-USG fusion targeted biopsy or USG-guided template biopsy: Clinical tumour stage \<=T2, or Gleason score \<=7, or PSA \<= 20 ng/ml
Exclusion
- Patients unfit for contrast MRI exam
- Patients with active urinary tract infection
- Patients with bladder pathology including bladder stone and bladder cancer
- Patients with urethral stricture
- Patients with neurogenic bladder and/or sphincter abnormalities
- Patients who fail to give informed consent
Key Trial Info
Start Date :
June 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06886321
Start Date
June 30 2025
End Date
June 30 2027
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, the Chinese University of Hong Kong
Hong Kong, Hong Kong